Cancer drug tested in pet dogs is now bound for human trials

July 17, 2013, University of Illinois at Urbana-Champaign

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

If PAC-1 (pack one) makes it through the U.S. Food and Drug Administration's Investigational New Drug review, the first human (Phase I) clinical trial of the drug will begin in mid-2014. The investor, who wishes to remain anonymous, has an option to invest another $2 million to take the drug into human trials. The clinical work will be conducted at the University of Illinois Cancer Center in Chicago.

"The trial is going to be geared toward brain patients," said U. of I. chemistry professor Paul Hergenrother, who discovered PAC-1's anti-cancer capabilities in 2006 and has been refining and testing it ever since. "One of the unusual features of this drug is that it does get into the brain, which most do not. So we want to embrace that and try to address the unmet clinical need of brain cancer."

The researchers noted that the compound is still in the early stages of development, and must pass toxicological tests in two species as well as other pharmacology toxicity testing before it can be tried in human subjects.

The new investment is the outgrowth of years of testing and development of PAC-1 and derivative compounds in dogs with naturally occurring cancers, said Illinois professor of veterinary clinical medicine Tim Fan, who coordinated clinical trials of the drug in canine patients at the U. of I. Veterinary Teaching Hospital.

"We know that mice will always be used as a traditional model for ," Fan said. "But conventional preclinical models use mice with induced cancers, which fail to faithfully recapitulate the development of natural cancers. This means that novel therapeutics that may be effective in mice might fail in patients that develop cancer spontaneously, as observed in both dogs and people."

The researchers emphasized that the dogs used in the testing of PAC-1 were pets from the community with spontaneously occurring cancers, not laboratory animals with induced cancers.

"In addition to paving the way for the human trial, we have helped many veterinary patients that would not have otherwise received treatments for their cancer," Fan said.

PAC-1 targets a cellular enzyme, procaspase-3, that when activated spurs a series of reactions inside the cell that cause it to self-destruct, Hergenrother said. Procaspase-3 has long been an attractive target for cancer therapy, in part because cancers often interfere with normal cell death, and in part because many tumors—including those of the breast, colon, liver and lung, along with lymphoma and melanoma—contain high levels of procaspase-3.

"The target, procaspase-3 activation, and the extensive amount of in vitro and animal data that Dr. Hergenrother and Dr. Fan had generated are what attracted me to this project," said Ted Tarasow, the chief executive officer of Vanquish Oncology, a development startup company founded by Hergenrother and Tarasow in 2011.

"Procaspase-3 activation has long been recognized as a high potential target for oncology therapeutics, but largely has been met with frustration in terms of finding compounds that could actually influence its activity in vivo," Tarasow said. "And so the compounds that professor Hergenrother developed and that Vanquish is pursuing are likely to be the first procaspase-3-activating agents to make it to the clinic despite a lot of interest and investment in this target over the years."

Vanquish Oncology "has exclusively licensed the technology from the University of Illinois and is focused on moving PAC-1 into the clinic," Tarasow said. "As with any investigational agent, determining the true safety and efficacy profile of PAC-1 will take several years of human clinical trials."

PAC-1 has other desirable attributes, said Arkadiusz Dudek, a physician and professor of hematology and oncology at the U. of I. at Chicago.

"What is interesting about Hergenrother's discovery is that it has a unique ability to penetrate to brain tumors," said Dudek, who will design and supervise the first PAC-1 clinical trial in humans at the U. of I. Cancer Center. "This is an area of interest for us. If successful, it will make a huge impact on survival, quality of life and disease control in patients with primary or metastatic brain tumors."

Explore further: Human and canine lymphomas share molecular similarities, first large-scale comparison shows

More information: www.ncbi.nlm.nih.gov/pmc/articles/PMC3113694/

Related Stories

Human and canine lymphomas share molecular similarities, first large-scale comparison shows

June 25, 2013
Humans and their pet dogs are close, so close that they both develop a type of cancer called diffuse large B-cell lymphoma. In humans it's the most common lymphoma subtype while in dogs, it's one of the most common cancers ...

Pets battling cancer can join clinical trials too

June 14, 2013
(HealthDay)—If you hear that a friend's beloved family member has joined a clinical trial for cancer treatment, don't assume the patient is human.

Standard chemotherapy provides higher survival rate than experimental in lung cancer patients

September 6, 2012
Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab ...

Research in mice identifies new treatment options for bowel cancer

July 8, 2013
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised ...

CU Cancer Center opens phase I clinical trial of anti-cancer stem cell agent OMP-54F28

October 3, 2012
The University of Colorado Cancer Center, together with other participating academic medical centers, recently opened a phase I human clinical trial of the drug OMP-54F28 in patients with advanced solid tumor cancers. OMP-54F28, ...

Recommended for you

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.